JEOL and SCiLS Sign a Distribution Agreement for SCiLS Lab MVS Software
8.6.2021 03:30:00 EEST | Business Wire | Press release
JEOL Ltd.(TOKYO:6951) (President & COO Izumi Oi) and SCiLS, a division of Bruker Daltonics, announced that they have concluded a non-exclusive, worldwide distribution agreement for SCiLS Lab MVS software.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210607005273/en/
MALDI-TOFMS imaging system (Graphic: Business Wire)
https://www.jeol.co.jp/en/products/detail/MS-Imaging.html
The SCiLS Lab has been the software of choice for researchers wanting to gain new insights from mass spectrometry imaging. Used in science and industry, the software sets new standards in analysis and visualization, simplifying everyday work and advancing the research. The SCiLS Lab MVS (Multi-Vender Support) can be used for the analysis of mass spectrometry imaging datasets based on the open imzML data format. SCiLS Lab MVS offers all features of SCiLS Lab and it allows the statistical analysis and visualization of mass spectrometry imaging data of virtually unlimited size in two and three spatial dimensions.
"We're very excited to work with JEOL to jointly disseminate the technology of mass spectrometry imaging and to support JEOL’s further development of their MALDI imaging solution ," Dennis Trede, co-founder of SCiLS and Director at Bruker Daltonics commented. "SCiLS Lab MVS – our software package for vendor-agnostic data analysis – offers the broadest possible compatibility for mass spectrometry imaging data of all vendors. The software enables to easily convert data into knowledge irrespective of which mass spectrometers the data come from."
“We are excited to offer SCiLS lab MVS software through our own sales channels,” said Yoshihisa Ueda, general manager of the mass spectrometry business unit of JEOL Ltd. “Highly sophisticated statistical analysis capability of SCiLS Lab MVS will benefit our SpiralTOF™-plus users considerably as they can now take full advantage of high mass-resolving power of SpiralTOF™-plus for their imaging MS researches.”
About SCiLS
SCiLS was founded in 2010 as a spin-off from the University of Bremen to develop and promote mathematical and computational software solutions for mass spectrometry imaging. Since 2017, SCiLS has been part of Bruker Corporation.
URL: www.scils.de
JEOL Ltd.
3-1-2, Musashino, Akishima, Tokyo, 196-8558, Japan
Izumi Oi, President & COO
(Stock code: 6951, Tokyo Stock Exchange First Section)
www.jeol.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210607005273/en/
Contact information
JEOL Ltd.
Science and Measurement Instruments Sales Division
SI Sales Promotion Department
MS Group
Toshihito YAMAMOTO
+81-3-6262-3575
E-mail: toyamamo@jeol.co.jp
https://www.jeol.co.jp/en/support/support_system/contact_products.html
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Investment Is Surging, but Businesses Are Struggling to Prove the Value, HTEC Global Study Finds15.10.2026 11:42:00 EEST | Press release
HTEC, a global product engineering and AI transformation company, today launches The HTEC AI Value Realization Report 2026, revealing a new challenge emerging as organizations move beyond AI experimentation: investment is accelerating faster than many companies’ ability to measure, govern and consistently realize its value. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015407055/en/ HTEC, a global product engineering and AI transformation company, today launches The HTEC AI Value Realization Report 2026, revealing a new challenge emerging as organizations move beyond AI experimentation: investment is accelerating faster than many companies’ ability to measure, govern and consistently realize its value. The independent study finds that 79% of organizations have increased AI investment over the past year, with spending rising by 31% on average. Yet 77% of executives now believe AI value is constrained more by people and pr
Flowdesk Europe Receives Payment Institution Authorization from the ACPR Under PSD215.10.2026 10:30:00 EEST | Press release
Flowdesk, a global liquidity provider and digital asset trading and infrastructure provider, today announced that its European entity, Flowdesk Europe, has been authorized as a Payment Institution by the French Prudential Supervision and Resolution Authority, l'Autorité de contrôle prudentiel et de résolution (ACPR), under the second Payment Services Directive (PSD2). The authorization allows Flowdesk Europe to provide custody and transfer services for e-money tokens (EMTs), the fiat-referenced stablecoins regulated under the Markets in Crypto-Assets (MiCA) regulation, to its clients across the European Union. The authorization follows the entity’s Crypto-Asset Service Provider (CASP) authorization received from the Autorité des Marchés Financiers (AMF) under MiCA at the end of June this year. With both authorizations in place, Flowdesk Europe can now support its EU clients across the trading, custody, and transfer of crypto-assets and EMTs, reflecting the firm’s long-standing commitme
Too Good To Go Expands Its Marketplace Beyond Food15.10.2026 10:30:00 EEST | Press release
Too Good To Go, the world's largest marketplace for surplus food, today announced that it is expanding its Marketplace beyond food, enabling retailers to redistribute surplus across personal care — including skincare, haircare, oral care and beauty products — pet care, flowers and plants, nutrition and supplements, and home, initially spanning cleaning and laundry products and décor. More than 8,500 stores already supply products across these areas, around one third of which were already working with Too Good To Go to redistribute surplus food. “In today’s society, we have built incredibly efficient processes for producing and selling things at scale, creating abundance, but we have not built the same efficiency into making sure what is left over gets used. As our lives have become more convenient, we have become less conscious of what those things are worth. We used to finish what was on the plate, find a use for what we had and instinctively pause before throwing something away. Too
From AI to Autonomous Networks: Mobileum Spark Highlights the Next Frontier of Telecom Intelligence15.10.2026 10:00:00 EEST | Press release
Mobileum Inc. ("Mobileum"), a leading global provider of telecom analytics and network solutions, brought together telecom operators and industry leaders during its Mobileum Spark events series in Lisbon (Portugal) and Frankfurt (Germany), to explore how Artificial Intelligence (AI), Agentic AI and automation are transforming network operations and accelerating the evolution toward autonomous networks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015172815/en/ Telecom operators, industry leaders, and Mobileum experts at Mobileum Spark 2026. Focused on Risk Management & Fraud Prevention and Network Testing & Assurance, the events featured customer-led discussions, expert insights, and real-world use cases demonstrating how AI and advanced automation are helping operators address increasing network complexity, strengthen fraud prevention, improve service assurance, and drive operational efficiency. A central theme across
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN ® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 09:00:00 EEST | Press release
Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month 6 as the primary endpoint. Secondary endpoints include changes in monthly headache days, acute medication days and migraine frequency during two-week periods at the end of each injection cycle. “Achieving patient recruitment for both MINT-C and MINT-E six months ahead of plan is an important milestone for our XEOMIN® migraine preven
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom